nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Extreme Hodgkin's lymphoma: current problem areas
|
Proctor, S.J. |
|
|
17 |
S4 |
p. iv15-iv17 |
artikel |
2 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study
|
Corazzelli, G. |
|
|
17 |
S4 |
p. iv18-iv24 |
artikel |
3 |
Guest Editor
|
|
|
|
17 |
S4 |
p. ii-iii |
artikel |
4 |
Histopathology in the light of molecular profiling
|
Stein, H. |
|
|
17 |
S4 |
p. iv5-iv7 |
artikel |
5 |
Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention
|
Lokiec, F. |
|
|
17 |
S4 |
p. iv33-iv36 |
artikel |
6 |
Managing large cell lymphoma
|
Gisselbrecht, C. |
|
|
17 |
S4 |
p. iv8-iv11 |
artikel |
7 |
Mantle cell lymphoma: an update on management
|
Zelenetz, A.D. |
|
|
17 |
S4 |
p. iv12-iv14 |
artikel |
8 |
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma
|
Hertzberg, M.S. |
|
|
17 |
S4 |
p. iv25-iv30 |
artikel |
9 |
Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation
|
Moskowitz, C.H. |
|
|
17 |
S4 |
p. iv37-iv39 |
artikel |
10 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study
|
Hagberg, H. |
|
|
17 |
S4 |
p. iv31-iv32 |
artikel |
11 |
Table of Contents
|
|
|
|
17 |
S4 |
p. iv |
artikel |